Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04121676 · ClinicalTrials.gov registry record · Phase 1
Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer
A Phase 1 study, sponsored by Agenus.
- Completed
- Registry status
- Phase 1
- Development phase
- 91
- Enrollment target
NCT04121676 is a Phase 1 study that has completed, run by Agenus. The registered enrollment target is 91 participants.
The verdict
NCT04121676, a Phase 1 study, has completed, sponsored by Agenus.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 91 participants
- Enrollment target
Study Summary
This study is an open-label, Phase 1, multicenter study to evaluate the safety, tolerability, PK, and PD profiles of AGEN2373 as a monotherapy and in combination with botensilimab (also known as AGEN1181), and to assess the maximum tolerated dose (MTD) in subjects with advanced solid tumors.
Interventions
- DRUG Botensilimab
- DRUG AGEN2373
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2019-09-26 |
| Est. Completion | 2024-11-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04121676
The ClinicalTrials.gov registry entry for NCT04121676 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 91 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Agenus, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Botensilimab is the first listed.
NCT04121676 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04121676 about?
NCT04121676 is a clinical study titled "Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer". This study is an open-label, Phase 1, multicenter study to evaluate the safety, tolerability, PK, and PD profiles of AGEN2373 as a monotherapy and in combination with botensilimab (also known as AGEN1181), and to assess the maximum tolerated dose (MTD) in subjects with advanced solid tumors.
What is the current status of trial NCT04121676?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 91 participants. The study started on 2019-09-26. Estimated completion is 2024-11-30.
What interventions are being tested in trial NCT04121676?
The interventions under investigation include: Botensilimab (DRUG), AGEN2373 (DRUG).
Who is sponsoring clinical trial NCT04121676?
This trial is sponsored by Agenus, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.